12:00 AM
Nov 22, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ADL 8-2698: Phase II

In Phase I and II trials involving a total of 118 patients treated with ADL 8-2698, the compound statistically significantly reversed narcotic-induced slowing of upper and lower...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >